Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramelteon in Chinese Patients With Chronic Insomnia
NCT06512363Phase 3Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Insomnia comparing Ramelteon 8 mg with Placebo (2 arms). Primary endpoint: Mean Latency to Persistent Sleep at Week 1. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
ramelteon
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06512363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512363.